WO2006093022A1 - 免疫機能調整剤 - Google Patents

免疫機能調整剤 Download PDF

Info

Publication number
WO2006093022A1
WO2006093022A1 PCT/JP2006/303295 JP2006303295W WO2006093022A1 WO 2006093022 A1 WO2006093022 A1 WO 2006093022A1 JP 2006303295 W JP2006303295 W JP 2006303295W WO 2006093022 A1 WO2006093022 A1 WO 2006093022A1
Authority
WO
WIPO (PCT)
Prior art keywords
allergy
lactobacillus
food
dried
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2006/303295
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
Toshihiro Sashihara
Makoto Yamaguchi
Yoshitaka Nakamura
Shuji Ikegami
Seiko Narushima
Katsunori Kimura
Shinya Nagafuchi
Masaki Terahara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Dairies Corp
Original Assignee
Meiji Dairies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Dairies Corp filed Critical Meiji Dairies Corp
Priority to KR1020137003716A priority Critical patent/KR101312745B1/ko
Priority to EP06714435.2A priority patent/EP1880726B1/en
Priority to JP2007505879A priority patent/JP4974881B2/ja
Priority to CA2599909A priority patent/CA2599909C/en
Priority to HK08110537.1A priority patent/HK1115067B/xx
Priority to CN2006800151753A priority patent/CN101171019B/zh
Priority to US11/817,617 priority patent/US9314041B2/en
Priority to AU2006219475A priority patent/AU2006219475B8/en
Publication of WO2006093022A1 publication Critical patent/WO2006093022A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/02—Making cheese curd
    • A23C19/032—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin
    • A23C19/0323—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin using only lactic acid bacteria, e.g. Pediococcus and Leuconostoc species; Bifidobacteria; Microbial starters in general
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Definitions

  • Lactic acid bacteria are preferred, because they produce flavor substances and have the ability to produce antibacterial substances such as lactic acid and bacteriocin, and have been eaten all over the world through fermented milk since ancient times. It is an extremely safe microorganism.
  • administration of Lactobacillus rnamnosus uG ⁇ (Lactobacillus rhamnosus ATCC ⁇ > ⁇ 103 strain), which is a type of lactic acid tooth, in double-blind placebo trials has suppressed the onset of atopic disease in high-risk children by about half.
  • Non-patent document 2 the use of lactic acid bacteria is an easy and effective method for preventing and treating or treating allergies without side effects.
  • the allergy preventing and Z or therapeutic agent of the present invention may contain the above-mentioned Lactobacillus gasseri as it is, or may contain Lactobacillus gasseri as a lactic acid bacterium treatment product!
  • Examples of the processed lactic acid bacteria used in the allergy prevention and Z or therapeutic agent of the present invention include lactic acid bacteria, lactic acid bacteria-containing products, concentrated fermented milk, basified products, and dried products (spray-dried products, freeze-dried products, and vacuum-dried products). Or at least one selected from the dry drum power), liquids, diluted products, crushed materials, and the like.
  • lactic acid bacteria viable cells, wet bacteria, dry bacteria and the like can be used as appropriate.
  • the allergy preventing and Z or therapeutic agent of the present invention can be used in the form of pharmaceuticals, foods and drinks, or misalignment.
  • various allergies by direct administration as pharmaceuticals, or by direct intake as special-purpose foods such as foods for specified health use or nutritional functional foods.
  • various drinks milk, processed milk, milk drinks, soft drinks, fermented milk, yogurt, cheese, bread, biscuit, crackers, pizza crust, ice cream, candy, prepared milk powder, liquid food, food for the sick, Add it to infant formula foods, lactating infant formula foods, nutritional foods, etc.) and take it.
  • the allergy prevention Z or therapeutic agent of the present invention is used for the production of a food composition or a drug
  • the production method can be carried out by methods well known to those skilled in the art. If it is an expert, the process which mixes the Lactobacillus gasseri microbial cell or processed material of this invention with another component, a shaping
  • the allergy preventing and Z or therapeutic agent of the present invention when used as a pharmaceutical, it can be administered in various forms.
  • the form include oral administration using tablets, capsules, granules, powders, syrups and the like.
  • These various preparations are usually used in the pharmaceutical preparation technical fields such as excipients, binders, disintegrating agents, lubricants, flavoring agents, solubilizing agents, suspending agents, coating agents, etc.
  • gasseri MEP170409 (Lactobacillus gasseri OLL2809 (accession number: NI TE BP-72)) have strong IL-12 production promoting activity. It has the power to improve the Thl / Th2 balance.
  • the fluorescence intensity in the supernatant (Excitation: 485 nm, Emission: 535 nm) was measured, and this value was used as the Test measurement value. Furthermore, the fluorescence intensity in the culture supernatant when cultured with spleen cells or YAC-1 cells alone was taken as the spleen cell Spontaneous measurement value and YAC-1 Spontaneous measurement value, respectively. In addition, after culturing only YAC-1 cells, Triton X100 (Wako Pure Chemical Industries) was added to destroy the cells, and the fluorescence intensity was taken as the total measurement value. Cytotoxic activity was calculated by applying these values to the following equation.
  • L. gasseri MEP170413 In L. gasseri MEP170413, a significant (p ⁇ 0.05) increase in IL-12 (p70) production from spleen cells was observed. IL-4 production was observed in both spleen cells and mesenteric lymph node cells. However, no effect was observed. L. crispatus JCM 1185 T showed no change in the cytokine production of these cells. Based on the above, L. gasseri OLL2809 (Accession No .: NITE BP-72) strain showed Thl / Th2 balance of spleen cells and mesenteric lymph node cells when administered orally to BALB / c mice administered intraperitoneally with OVA. It was found that there was an improvement effect.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Dairy Products (AREA)
PCT/JP2006/303295 2005-03-03 2006-02-23 免疫機能調整剤 Ceased WO2006093022A1 (ja)

Priority Applications (8)

Application Number Priority Date Filing Date Title
KR1020137003716A KR101312745B1 (ko) 2005-03-03 2006-02-23 면역기능 조정제
EP06714435.2A EP1880726B1 (en) 2005-03-03 2006-02-23 Immune function modulating agents
JP2007505879A JP4974881B2 (ja) 2005-03-03 2006-02-23 免疫機能調整剤
CA2599909A CA2599909C (en) 2005-03-03 2006-02-23 Immune function modulating agents
HK08110537.1A HK1115067B (en) 2005-03-03 2006-02-23 Immune function modulating agent
CN2006800151753A CN101171019B (zh) 2005-03-03 2006-02-23 免疫功能调节剂
US11/817,617 US9314041B2 (en) 2005-03-03 2006-02-23 Immune function modulating agents
AU2006219475A AU2006219475B8 (en) 2005-03-03 2006-02-23 Immune function modulating agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005059460 2005-03-03
JP2005-059460 2005-03-03

Publications (1)

Publication Number Publication Date
WO2006093022A1 true WO2006093022A1 (ja) 2006-09-08

Family

ID=36941056

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/303295 Ceased WO2006093022A1 (ja) 2005-03-03 2006-02-23 免疫機能調整剤

Country Status (9)

Country Link
US (1) US9314041B2 (https=)
EP (1) EP1880726B1 (https=)
JP (1) JP4974881B2 (https=)
KR (2) KR101312745B1 (https=)
CN (1) CN101171019B (https=)
AU (1) AU2006219475B8 (https=)
CA (1) CA2599909C (https=)
TW (1) TW200642692A (https=)
WO (1) WO2006093022A1 (https=)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007138993A1 (ja) * 2006-05-31 2007-12-06 Meiji Dairies Corporation 免疫調節活性の高い乳酸菌の培養法
JP2008169198A (ja) * 2007-01-05 2008-07-24 Promd Biotech Co Ltd 抗アレルギーの乳酸菌
WO2009057743A1 (ja) * 2007-11-02 2009-05-07 Kirin Holdings Kabushiki Kaisha 乳酸菌含有抗アレルギー用飲料
JP2012510291A (ja) * 2008-12-03 2012-05-10 シージェイ チェイルジェダン コーポレーション 新規なラクトバチルス・プランタラム及びこれを含む組成物
WO2012073924A1 (ja) * 2010-11-29 2012-06-07 株式会社明治 子宮内膜症の予防及び／又は改善剤及びこれを含んでなる飲食品組成物
WO2012081650A1 (ja) * 2010-12-16 2012-06-21 株式会社明治 遅延型過敏症軽減剤
JP2012533319A (ja) * 2009-07-22 2012-12-27 シージェイ チェイルジェダン コーポレーション 新規なラクトバチルス・プランタラム及びこれを含む組成物
JP2012533290A (ja) * 2009-07-14 2012-12-27 シージェイ チェイルジェダン コーポレーション 新規なラクトバチルス・プランタラム及びこれを含む組成物
JP2013047192A (ja) * 2011-08-29 2013-03-07 Meiji Co Ltd 身体活動を促進させる乳酸菌
JP2016106140A (ja) * 2003-04-24 2016-06-16 ショウ，コウ ジン 醗酵乳製品およびその使用
CN110305843A (zh) * 2019-07-12 2019-10-08 赛德特生物科技开发有限公司 可以改善自身免疫性疾病的免疫细胞及其制备方法与应用
JP2020000033A (ja) * 2018-06-26 2020-01-09 国立大学法人広島大学 経口免疫寛容誘導剤、これを含有する食品および医薬品、ならびに加工食品の製造方法
JP2021524748A (ja) * 2018-05-23 2021-09-16 コ・バイオラブズ・インコーポレイテッド ラクトバチルス・ガッセリーｋｂｌ６９７株及びその使用
WO2022176174A1 (ja) * 2021-02-19 2022-08-25 株式会社 資生堂 免疫細胞活性化剤、抗老化剤、免疫細胞の活性化方法、及び老化を防止又は予防する方法
US11920124B2 (en) 2019-04-15 2024-03-05 Cell Biotech Co., Ltd. Method of producing lactic acid bacteria dual-coated with protein and polysaccharide by using protein hydrolysate

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI386163B (zh) * 2007-01-05 2013-02-21 Promd Biotech Co Ltd 抗過敏之乳酸菌
EP2221360B1 (en) * 2007-11-30 2014-03-05 Meiji Co., Ltd. Lactic acid bacterium having effect of lowering blood uric acid level
TW201106957A (en) * 2009-08-31 2011-03-01 Synbio Tech Inc The new strain of Lactobacillus plantarum LP28 and its use in treating allergy
KR101178217B1 (ko) 2009-10-28 2012-09-07 씨제이제일제당 (주) 신규한 락토바실러스 플란타룸 및 이를 포함하는 조성물
TWI381858B (zh) * 2009-12-16 2013-01-11 Chih Hao Chang 女性私密處清潔劑及其製造方法
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
EE05721B1 (et) * 2011-02-25 2014-08-15 OÜ Tervisliku Piima Biotehnoloogiate Arenduskeskus Isoleeritud mikroorganismi tüvi L. plantarum MCC1 DSM 23881 ja selle kasutamine
CN116942833A (zh) 2011-12-01 2023-10-27 国立大学法人 东京大学 诱导调节性t细胞的增殖或积累的人源细菌
US8647684B2 (en) 2012-02-01 2014-02-11 Howard Baube pH modified insect repellent/insecticide soap composed of plant essential oils
CN105026549B (zh) * 2012-12-07 2021-03-16 韩国生命源株式会社 具有诱导il-12产生的能力的乳酸杆菌以及用于培养其的方法
JP5927730B2 (ja) * 2013-04-11 2016-06-01 アサヒグループホールディングス株式会社 免疫調節作用を有する乳酸菌のスクリーニング方法
JP7168558B2 (ja) 2016-06-14 2022-11-09 ヴェダンタ バイオサイエンシーズ インコーポレーテッド Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置
CN109715784A (zh) * 2016-09-16 2019-05-03 杜邦营养生物科学有限公司 细菌
AU2019274350B2 (en) 2018-05-23 2022-04-07 Kobiolabs, Inc. Lactobacillus crispatus KBL693 strain and use thereof
WO2020037271A1 (en) * 2018-08-17 2020-02-20 Vedanta Biosciences, Inc. Methods of decreasing dysbiosis and restoring a microbiome
KR101953072B1 (ko) * 2018-11-09 2019-02-27 에스케이바이오랜드 주식회사 신규한 락토바실러스 가세리 skb1102 균주 또는 이를 함유하는 안티폴루션 기능이 있는 화장료 조성물
CN111248268A (zh) * 2018-11-30 2020-06-09 内蒙古伊利实业集团股份有限公司 一种发酵乳及其制备方法
US11242997B2 (en) 2019-09-12 2022-02-08 K C Grace Portable propane fuel heater assembly
BR112022019244A2 (pt) * 2020-04-07 2022-11-08 Hofseth Biocare Asa Método para reduzir a função efetora de eosinófilos, artigo de fabricação e kit
CN111909882B (zh) * 2020-09-10 2022-05-13 青岛普罗百世生物科技有限公司 一种副干酪乳杆菌及其在宠物犬犬粮中的应用
TWI776433B (zh) * 2021-03-22 2022-09-01 生合生物科技股份有限公司 戴白氏乳桿菌乳酸亞種ldl557分離株及其用途
CN114081854B (zh) * 2021-11-19 2023-08-15 烟台新时代健康产业日化有限公司 一种具有屏障修复功能的松花粉提取物及其发酵制备工艺

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003095963A (ja) * 2001-09-20 2003-04-03 Snow Brand Milk Prod Co Ltd 炎症性腸疾患及び過敏性腸症候群の予防・治療剤
JP2003253262A (ja) * 2002-02-28 2003-09-10 Snow Brand Milk Prod Co Ltd 抗酸化剤
JP2003252772A (ja) * 2002-03-04 2003-09-10 Snow Brand Milk Prod Co Ltd 加齢に伴う代謝異常症の予防・改善・治療剤
JP2003306436A (ja) * 2002-02-15 2003-10-28 Snow Brand Milk Prod Co Ltd 血清コレステロール上昇抑制剤
WO2004003235A2 (en) 2002-06-28 2004-01-08 Puleva Biotech, S.A. Probiotic strains, a process for the selection of them, compositions thereof, and their use
JP2004018469A (ja) 2002-06-18 2004-01-22 National Agriculture & Bio-Oriented Research Organization 抗アレルギー剤
JP2004026729A (ja) 2002-06-26 2004-01-29 Calpis Co Ltd 抗アレルギー剤
JP2004091491A (ja) 2002-09-02 2004-03-25 Genmont Biotech Inc アレルギーを処置する際のいくつかのＬａｃｔｏｂａｃｉｌｌｕｓ株の新規使用
JP2004250337A (ja) 2003-02-18 2004-09-09 Sunstar Inc アレルギー疾患改善用製剤
JP3585487B1 (ja) 2003-03-13 2004-11-04 麒麟麦酒株式会社 抗アレルギー用組成物
JP2004315477A (ja) * 2003-04-18 2004-11-11 Tokyoto Koreisha Kenkyu Fukushi Shinko Zaidan 骨吸収抑制剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH092959A (ja) 1995-06-16 1997-01-07 Yakult Honsha Co Ltd ＩｇＥ抗体産生抑制剤および抗アレルギー剤
JPH09259A (ja) 1995-06-20 1997-01-07 Yakult Honsha Co Ltd β−ガラクトシダーゼ産生プラスミド及びβ−ガラクトシダーゼの製造法
EP1239032A1 (en) * 2001-03-02 2002-09-11 Société des Produits Nestlé S.A. Lactic acid bacteria as agents for treating and preventing allergy
US20040071679A1 (en) 2002-10-15 2004-04-15 Claudio De Simone Identifying and treating vaginal infections
JP2004154035A (ja) * 2002-11-06 2004-06-03 Combi Corp 乳酸菌発酵食品の製造方法、該方法によって得られる乳酸菌発酵食品及び便通改善剤

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003095963A (ja) * 2001-09-20 2003-04-03 Snow Brand Milk Prod Co Ltd 炎症性腸疾患及び過敏性腸症候群の予防・治療剤
JP2003306436A (ja) * 2002-02-15 2003-10-28 Snow Brand Milk Prod Co Ltd 血清コレステロール上昇抑制剤
JP2003253262A (ja) * 2002-02-28 2003-09-10 Snow Brand Milk Prod Co Ltd 抗酸化剤
JP2003252772A (ja) * 2002-03-04 2003-09-10 Snow Brand Milk Prod Co Ltd 加齢に伴う代謝異常症の予防・改善・治療剤
JP2004018469A (ja) 2002-06-18 2004-01-22 National Agriculture & Bio-Oriented Research Organization 抗アレルギー剤
JP2004026729A (ja) 2002-06-26 2004-01-29 Calpis Co Ltd 抗アレルギー剤
WO2004003235A2 (en) 2002-06-28 2004-01-08 Puleva Biotech, S.A. Probiotic strains, a process for the selection of them, compositions thereof, and their use
JP2004091491A (ja) 2002-09-02 2004-03-25 Genmont Biotech Inc アレルギーを処置する際のいくつかのＬａｃｔｏｂａｃｉｌｌｕｓ株の新規使用
JP2004250337A (ja) 2003-02-18 2004-09-09 Sunstar Inc アレルギー疾患改善用製剤
JP3585487B1 (ja) 2003-03-13 2004-11-04 麒麟麦酒株式会社 抗アレルギー用組成物
JP2004315477A (ja) * 2003-04-18 2004-11-11 Tokyoto Koreisha Kenkyu Fukushi Shinko Zaidan 骨吸収抑制剤

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AKAHOSHI M; TAMARI M; SHIROKAWA T: "Recent Topics in Allergic Diseases", SAISHIN IGAKU, vol. 58, no. 2, 2003, pages 7 - 14
HO F ET AL: "Allergy-sei Shikkan ni Taisuru Fukugo Probiotics Nyusankin no Yuekisei. (Effects of combination of probiotic lactic acid bacteria to allergic disorder)", ALLERGY NO RINSHO, vol. 26, no. 2, 20 February 2006 (2006-02-20), pages 140 - 144, XP003001543 *
HO F ET AL: "Probiotics Nyusankin Lactobacillus gasseri TMC0356 Kabu no Men'eki Shushoku oyobi Ko Allergy Sayo. (Immuno-modulatory and anti-allergic effects of probiotic lactic bacteria, Lactobacillus gasseri TMC0356)", ALLERGY NO RINSHO, vol. 25, no. 12, 20 November 2005 (2005-11-20), pages 75 - 80, XP003001544 *
ISE W: "Progress in the studies of food allergy control; recognition of food allergen by the intestinal immune system", AGRICULTURE, FORESTRY AND FISHERIES TECHNICAL RESEARCH JOURNAL, vol. 24, no. 5, 2001, pages 9 - 14
KALLIOMAKI M; SALMINEN S; ARVILOMMI H; KERO P; KOSKINEN P; ISOLAURI E.: "Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial", LANCET, vol. 357, no. 9262, 2001, pages 1076 - 1079, XP005061313, DOI: doi:10.1016/S0140-6736(00)04259-8
NAIDU AS; BIDLACK WR; CLEMENS RA: "Probiotic spectra of lactic acid bacteria (LAB", CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, vol. 39, no. 1, 1999, pages 13 - 126
See also references of EP1880726A4 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016106140A (ja) * 2003-04-24 2016-06-16 ショウ，コウ ジン 醗酵乳製品およびその使用
WO2007138993A1 (ja) * 2006-05-31 2007-12-06 Meiji Dairies Corporation 免疫調節活性の高い乳酸菌の培養法
JP2008169198A (ja) * 2007-01-05 2008-07-24 Promd Biotech Co Ltd 抗アレルギーの乳酸菌
WO2009057743A1 (ja) * 2007-11-02 2009-05-07 Kirin Holdings Kabushiki Kaisha 乳酸菌含有抗アレルギー用飲料
JP2012510291A (ja) * 2008-12-03 2012-05-10 シージェイ チェイルジェダン コーポレーション 新規なラクトバチルス・プランタラム及びこれを含む組成物
JP2012533290A (ja) * 2009-07-14 2012-12-27 シージェイ チェイルジェダン コーポレーション 新規なラクトバチルス・プランタラム及びこれを含む組成物
JP2012533319A (ja) * 2009-07-22 2012-12-27 シージェイ チェイルジェダン コーポレーション 新規なラクトバチルス・プランタラム及びこれを含む組成物
JPWO2012073924A1 (ja) * 2010-11-29 2014-05-19 株式会社明治 子宮内膜症の予防及び／又は改善剤及びこれを含んでなる飲食品組成物
WO2012073924A1 (ja) * 2010-11-29 2012-06-07 株式会社明治 子宮内膜症の予防及び／又は改善剤及びこれを含んでなる飲食品組成物
JP2015044822A (ja) * 2010-11-29 2015-03-12 株式会社明治 子宮内膜症の予防及び／又は改善剤及びこれを含んでなる飲食品組成物
WO2012081650A1 (ja) * 2010-12-16 2012-06-21 株式会社明治 遅延型過敏症軽減剤
JPWO2012081650A1 (ja) * 2010-12-16 2014-05-22 株式会社明治 遅延型過敏症軽減剤
WO2013031749A1 (ja) * 2011-08-29 2013-03-07 株式会社明治 身体活動を促進させる乳酸菌
JP2013047192A (ja) * 2011-08-29 2013-03-07 Meiji Co Ltd 身体活動を促進させる乳酸菌
JP2021524748A (ja) * 2018-05-23 2021-09-16 コ・バイオラブズ・インコーポレイテッド ラクトバチルス・ガッセリーｋｂｌ６９７株及びその使用
JP7088573B2 (ja) 2018-05-23 2022-06-21 コバイオラブズ・インコーポレイテッド ラクトバチルス・ガッセリーｋｂｌ６９７株及びその使用
JP2020000033A (ja) * 2018-06-26 2020-01-09 国立大学法人広島大学 経口免疫寛容誘導剤、これを含有する食品および医薬品、ならびに加工食品の製造方法
US11920124B2 (en) 2019-04-15 2024-03-05 Cell Biotech Co., Ltd. Method of producing lactic acid bacteria dual-coated with protein and polysaccharide by using protein hydrolysate
CN110305843A (zh) * 2019-07-12 2019-10-08 赛德特生物科技开发有限公司 可以改善自身免疫性疾病的免疫细胞及其制备方法与应用
CN110305843B (zh) * 2019-07-12 2020-06-02 赛德特生物科技开发有限公司 可以改善自身免疫性疾病的免疫细胞及其制备方法与应用
WO2022176174A1 (ja) * 2021-02-19 2022-08-25 株式会社 資生堂 免疫細胞活性化剤、抗老化剤、免疫細胞の活性化方法、及び老化を防止又は予防する方法

Also Published As

Publication number Publication date
CA2599909A1 (en) 2006-09-08
TW200642692A (en) 2006-12-16
KR20070110115A (ko) 2007-11-15
EP1880726B1 (en) 2017-04-19
TWI359668B (https=) 2012-03-11
KR101260533B1 (ko) 2013-05-06
CN101171019B (zh) 2012-05-23
US9314041B2 (en) 2016-04-19
JP4974881B2 (ja) 2012-07-11
EP1880726A4 (en) 2012-01-11
KR20130020737A (ko) 2013-02-27
CN101171019A (zh) 2008-04-30
JPWO2006093022A1 (ja) 2008-08-07
US20090269321A1 (en) 2009-10-29
KR101312745B1 (ko) 2013-09-27
AU2006219475B2 (en) 2012-07-26
AU2006219475A1 (en) 2006-09-08
HK1115067A1 (en) 2008-11-21
AU2006219475B8 (en) 2013-02-07
CA2599909C (en) 2014-12-02
EP1880726A1 (en) 2008-01-23

Similar Documents

Publication Publication Date Title
JP4974881B2 (ja) 免疫機能調整剤
EP1951273B1 (en) Use of lactobacillus for treatment of autoimmune diseases
KR101355770B1 (ko) 면역조절 활성이 높은 유산균의 배양법
JP5527690B2 (ja) 免疫調節性機能誘導剤及び食品組成物
JP5273695B2 (ja) ビフィズス菌を有効成分とするアレルギー予防および／または治療剤
JP6823302B2 (ja) 乳児向けの抗アレルギー剤
EP2220210A1 (en) Strains of lactobacillus plantarum as probiotics with immunomodulatory specific effect
JP5937015B2 (ja) 遅延型過敏症軽減剤
JP6016326B2 (ja) 乳酸菌のスクリーニング方法
EP2332557A1 (en) Probiotic lactic acid bacteria
JP2007099628A (ja) 免疫機能調節剤および免疫機能調節用飲食品
HK1115067B (en) Immune function modulating agent
JP5851242B2 (ja) チオレドキシン誘導活性を有する乳酸菌ならびにチオレドキシンを介する生体傷害の予防および／または改善用の飲食品および医薬品
HK1130284B (en) Method for culture of lactic acid bacterium having high immunomodulating activity
HK1184187B (en) Lactic bacterium having an effect of ameliorating metabolic syndrome
HK1184187A1 (en) Lactic bacterium having an effect of ameliorating metabolic syndrome

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680015175.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007505879

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2599909

Country of ref document: CA

Ref document number: 12007501878

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 6815/DELNP/2007

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006219475

Country of ref document: AU

REEP Request for entry into the european phase

Ref document number: 2006714435

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006714435

Country of ref document: EP

Ref document number: 1020077022537

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 1200702015

Country of ref document: VN

ENP Entry into the national phase

Ref document number: 2006219475

Country of ref document: AU

Date of ref document: 20060223

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006219475

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006714435

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11817617

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1020137003716

Country of ref document: KR